IXICO plc provided information on its agreement with Life Molecular Imaging (LMI) for the supply of LMI's Neuraceq Amyloid PET tracer (Florbetaben-18F) for use in pharma-sponsored clinical trials. Neuraceq is a diagnostic agent that improves early detection and characterization of chronic and life-threatening diseases such as Alzheimer's, leading to better therapeutic outcomes and improved quality of life. As a result of its agreement with LMI, IXICO is able to further extend its service offering to providing Neuraceq PET tracer supply to complement IXICO's well-established PET imaging services and image data analytics.

LMI's provision of tracer supply to imaging centres together with IXICO's oversight of imaging will minimise the operational burden to trial sponsors and will improve patient experience, ultimately driving study eligibility and efficacy endpoint delivery.